Get notified of page updates

Search Results: Treatment + Colorectal Cancer + Stage 4 (7 results)

New Search
PRINTER FRIENDLY PAGE 1 through 7 of 7

Treatment
Treatment study for people with advanced or metastatic cancers

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

Clinicaltrials.gov identifier: NCT06974110

Treatment
Treatment study for people with advanced or metastatic solid tumors

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

Clinicaltrials.gov identifier: NCT06167317

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 

Clinicaltrials.gov identifier: NCT06022029

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.

Clinicaltrials.gov identifier: NCT05253651

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. People will have blood drawn and complete a questionnaire to join the study. Genetic testing will be done on your blood and the tissue from your tumor biopsy or surgery to test the genes that you inherited. You do not have to pay for the genetic testing. You will receive the results of your test from your oncologist and genetic counseling may be recommended. Two weeks and one year after talking with your doctor about your test results, you will complete follow-up questionnaires either in person or over the phone. 

ASCO TAPUR: Targeted Agent and Profiling Utilization Registry Study.

Treatment
Cancer treatment study for people with advanced solid tumors

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Clinicaltrials.gov identifier: NCT02693535

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Clinicaltrials.gov identifier: NCT03607890
Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
61 results
Clinical Trial Official Title
NCT05277051 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05379985 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT04668872 Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
NCT04314401 National Cancer Institute "Cancer Moonshot Biobank"
NCT04739072 Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
NCT06896162 PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT04684862 Infusion System for Hepatic Cancer
NCT06696768 Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
NCT04587128 Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT03965234 Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT02838836 Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT04693377 Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
NCT07044362 Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
NCT04339374 Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
NCT05200442 A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT05286814 PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT05691491 Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT05803382 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT05786924 Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT06336902 Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer
NCT03823144 Intravital Microscopy in Human Solid Tumors
NCT05248581 Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
NCT06603818 Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
NCT06349642 Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT05489211 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT06974110 Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06349590 Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
NCT04485013 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT05517811 Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT04701476 TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
NCT06300463 Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT04977453 GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
NCT04638751 ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT05400122 Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT04329494 PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT06342440 Early Detection of Advanced Adenomas and Colorectal Cancer
NCT06073431 An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06654037 Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT05863195 Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT04704661 Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT07153614 Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy
NCT06358677 Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
NCT07148128 Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT04899908 Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT06563388 Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT06833866 Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
NCT06102902 Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT05673148 Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT06047379 Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06269978 Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT05592626 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05239546 Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT01365169 Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT07125729 Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT05520099 Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT06885034 A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
NCT06130280 A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
NCT05086692 A Beta-only IL-2 ImmunoTherapY Study
NCT05733000 CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT06130826 Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Sponsored By